David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc. (NASDAQ:MLYS), executed a package of transactions on February 12 and 13, 2026 that included both open-market sales and option exercises.
Rodman sold a total of 14,676 shares of Mineralys common stock for aggregate proceeds of approximately $569,809. The individual sale prices in those transactions ranged from $27.33 to $29.6387 per share.
On the same two days, Rodman also acquired 14,056 shares through exercises of stock options. The option exercise prices ranged from $1.08 to $14.25 per share, for a combined cost of $102,340.
Company filings indicate these transactions were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that Rodman adopted on October 6, 2025. Following the completion of the sales and exercises, Rodman directly owns 44,089 shares of Mineralys Therapeutics.
Clinical and equity-market context
Mineralys has reported progress with its lead investigational drug, lorundrostat, which targets uncontrolled or treatment-resistant hypertension. The companies Phase 3 Launch-HTN trial for lorundrostat was highlighted by JAMA as one of the most impactful studies in its Research of the Year Roundup, a recognition the company has cited as notable within the medical community.
Following the trial data, Stifel increased its price target for Mineralys to $52 from $45 and reiterated a Buy rating, citing the strength of the trial results. The company is proceeding with preparations for a New Drug Application for lorundrostat.
At the same time, Mineralys shares moved lower after recent insider sales executed by Chief Executive Officer Jon Congleton and Chief Financial Officer Scott Levy. Those earlier transactions by the two executives totaled in excess of $14 million.
Key points
- Rodman sold 14,676 shares for about $569,809, with sale prices between $27.33 and $29.6387 per share - relevant to equity investors and capital markets observers.
- He exercised 14,056 options at prices from $1.08 to $14.25, paying $102,340 in total - a detail of interest to shareholders tracking insider ownership and compensation.
- Mineralys advance of lorundrostat - including JAMA recognition and a higher price target from Stifel - contrasts with recent sizable insider sales by the CEO and CFO, which coincided with a decline in the stock.
Risks and uncertainties
- Insider sales by company executives, including the CEO and CFOs transactions exceeding $14 million, correlated with a decline in the share price - a market reaction that investors may view as an uncertainty in equity sentiment.
- While lorundrostat has received recognition and prompted regulatory filings preparations, the ultimate outcome of the New Drug Application process remains to be determined and could affect the healthcare and biotech sectors.
- Changes in insider ownership levels following the sales and option exercises alter the insiders holdings and may influence perceptions among capital markets participants.
These facts are drawn from company transaction reports and recent disclosures regarding Mineralys Therapeutics clinical and market developments.